Webinar

The Evolution of Liver Cancer Market in 2024 (APAC)

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Join Bloomberg virtually on July 23 as we discuss the current landscape of liver cancer treatment with Dr. Leslie Oleksowicz, who directs a specialized multi-disciplinary hepatocellular cancer program at the University of Cincinnati medical center, including potential advances in the treatment of early stage disease after trial successes from AstraZeneca and Roche and the evolving first line landscape.

Speakers

Max Nisen

Analyst

Bloomberg Intelligence

Max Nisen is a senior associate equity research analyst specializing in the pharmaceutical and biotechnology sector. Prior to joining Bloomberg Intelligence, Max was the founding health care columnist for Bloomberg Gadfly and later Bloomberg Opinion, where he wrote about the pharmaceutical industry, managed care, policy and public health. Before that, he covered business and financial news at Quartz and Business Insider. Max earned a bachelor’s degree in economics from Pomona College.

Dr. Leslie Oleksowicz

Professor of Medial Oncology

Saint Louis University Cancer Center

Leslie Oleksowicz is Professor of Medicine at Saint Louis University Cancer Center (08/2012-present). Additionally, she has a voluntary faculty appointment as Director of Medical Genitourinary Oncology, Melanoma/Sarcoma Oncology and Immuno-Oncology at The Barrett Cancer Center of University Hospital, University of Cincinnati (09/2003-present). She specializes in the treatment of genitourinary cancer including prostate, bladder, urothelial, testicular and renal cell tumors, as well as melanoma, and sarcoma. She is a pioneer in the use of dose-intensive high dose Interleukin-2 for metastatic renal cell carcinoma and melanoma. She is currently involved in clinical trials for Stage IV breast cancer, melanoma, carcinoma, myeloma, and osteonecrosis. She is the Director of the Hematology/Oncology Clinical Trial Program and oversees a robust and comprehensive selection of clinical trials in the benign and malignant hematologic disorder space. She has served as an investigator in early clinical trials evaluating Ruxolitinib, Fedratinib Pacritnib and non-JAK inhibitors. She also has knowledge and can discuss novel investigational agents vying for approval in the MF space. Dr. Oleksowicz has written over 100 peer-reviewed publications and book chapters in major cancer journals and has served as the lead investigator in over 300 clinical trials. Over the span of her career, she has presented her research at national and international symposia, annual cancer conferences, web-based seminars and local lectures. Dr. Oleksowicz is also a reviewer for multiple cancer journals including Cancer, Transfusion, Journal of Medical Oncology, the Southern Journal of Medicine and the Journal of Urology.

Access a broad range of analysis, research, insight and actionable ideas with Bloomberg webinars.